GlassScriptPhysician profile
Robert K Vincent
NPI 1386870095
$7,191.07
in general payments reported to CMS, 2019-2025
30 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $627 · 2021: $1,197 · 2022: $1,070 · 2023: $1,259 · 2024: $966 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561 · Education: $24.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,561.31 |
| Education | $24.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,289.85 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $729.05 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $681.15 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.75 | 2019-2023 | Xifaxan |
| Pfizer INC. | $310.06 | 2019-2025 | |
| Gilead Sciences, INC. | $225.00 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $223.42 | 2021-2023 | |
| Madrigal Pharmaceuticals | $218.47 | 2025 | Rezdiffra |
| Romark Laboratories, Lc | $113.68 | 2019-2020 | |
| Ardelyx, INC. | $100.27 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $96.15 | 2020-2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $87.10 | 2020-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $74.42 | 2020-2023 | Linzess |
| Lilly USA, LLC | $55.83 | 2024-2025 | Omvoh |
| Ucb, INC. | $53.79 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $51.53 | 2020-2022 | |
| Shire North American Group INC | $51.40 | 2019 | |
| Mauna Kea Technologies, INC. | $47.76 | 2024 | |
| Braintree Laboratories, INC. | $46.74 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $36.75 | 2023-2025 | Ocaliva |
| Daiichi Sankyo INC. | $28.65 | 2023 | Injectafer |
| Redhill Biopharma INC. | $27.66 | 2021 | |
| Laborie Medical Technologies Corp. | $27.52 | 2023 | |
| Tersera Therapeutics LLC | $23.46 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $22.51 | 2025 | |
| Qol Medical, LLC | $16.06 | 2023 | Sucraid |
| Amgen INC. | $15.78 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $14.78 | 2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$21,955.68 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.